Clinical-stage life sciences company Revelation Biosciences Inc (NASDAQ: REVB) announced on Monday that Gemini priming significantly reduces inflammation in human peripheral blood mononuclear cells (PBMCs) exposed to inflammatory stimuli. The company anticipates similar protective effects in its Phase 1b clinical study in chronic kidney disease (CKD) patients, expected to report top-line data by mid-2025.

In the study, PBMCs primed with Gemini demonstrated a notable reduction in proinflammatory cytokines and an increase in anti-inflammatory cytokines compared to placebo when challenged with high mobility group box protein-1 (HMGB-1) and lipopolysaccharide (LPS). These results suggest Gemini's potential to mitigate inflammation-related damage.

As part of the PRIME Phase 1b trial, Revelation is evaluating PBMC responses in patients with Stage 3 and 4 CKD. Findings will support development programs targeting CKD, acute kidney injury (AKI), and post-surgical infection (PSI). Gemini, an intravenously administered formulation of phosphorylated hexaacyl disaccharide (PHAD®), reprograms the innate immune system to moderate its inflammatory response.

Revelation has conducted multiple preclinical and Phase 1 studies demonstrating Gemini's safety and pharmacodynamic activity, positioning it as a potential treatment to reduce inflammation-related complications in kidney disease and surgical recovery.